Class / Patent application number | Description | Number of patent applications / Date published |
424243100 | Staphylococcus (e.g., Staphylococcus aureus, etc.) | 27 |
20090092639 | IMMUNOGENIC COMPOSITION - Methods and compositions for increasing antibody titer in egg yolks and for using the antibodies are disclosed. | 04-09-2009 |
20090202593 | Novel immunogenic compositions for the prevention and treatment of meningococcal disease - The present invention relates to | 08-13-2009 |
20100021503 | IMMUNOGENIC COMPOSITION - The present application relates to immunogenic compositions comprising Type 5 and Type 8 capsular polysaccharide or oligosaccharide from | 01-28-2010 |
20100104603 | USE OF STAPHYLOCOCCAL SUPERANTIGEN-LIKE PROTEIN 5 (SSL5) IN MEDICINE - The present invention relates to Staphylococcal superantigen-like protein 5 (SSL5) or homologues or derivatives thereof for use in medicine, in particular for use in the treatment of indications involving an excessive recruitment of leukocytes, such as stroke, perfusion/ischemia, transplant rejection, rheumatoid arthritis. The invention further relates to a pharmaceutical composition comprising SSL5 and a suitable excipient. The invention also provides the use of SSL5 for the preparation of a medicament for treatment of indications involving an excessive recruitment of leukocytes to a site of tissue damage, such as stroke, reperfusion/ischemic, transplant rejection and rheumatoid arthritis. | 04-29-2010 |
20100158952 | MICROORGANISMS OR FRACTIONS THEREOF CAPABLE OF ACTIVATING CELLULAR IMMUNITY AGAINST CARBOHYDRATES - The present invention relates to the field of prevention and treatment of tumors and gastrointestinal disorders. The present invention relates to the prevention and treatment of Core-1-positive carcinomas. The invention relates to coreotics and a method of producing the same and to a method of prevention and treatment of core-1 positive disorders using the same. The invention relates to microorganisms or fractions thereof capable of activating cellular immunity against carbohydrates. | 06-24-2010 |
20100189748 | INACTIVATED STAPHYLOCOCCAL WHOLE-CELL VACCINE - A vaccine is disclosed that is protective against pathogenic bacterial species, typically staphylococcal species, and includes methods to prepare said vaccine and to culture pathogenic bacteria. | 07-29-2010 |
20100196422 | NOVEL POLYPEPTIDES FOR ISOLATING IN VITRO AND PREVENTING STAPHYLOCCOCAL INFECTIONS ON JOINT PROSTHESES AND OTHER IMPLANTED FOREIGN MATERIALS - The invention concerns novel polypeptides, or parts or variants of the novel polypeptides, the use of sequences encoding the polypeptides and the use of antibodies directed against the polypeptides in the field of in vitro diagnosis of a | 08-05-2010 |
20100260801 | Polysaccharide vaccine for staphylococcal infections - The invention relates to compositions of the capsular polysaccharide/adhesin (PS/A) of staphylococci. The PS/A may be isolated or synthesized and includes various modifications to the structure of native PS/A based on the chemical characterization of PS/A. The invention also relates to the use of the PS/A as a vaccine for inducing active immunity to infections caused by | 10-14-2010 |
20100330124 | VACCINE COMPOSITIONS AND METHODS OF USE TO PROTECT AGAINST INFECTIOUS DISEASE - The present invention provides a novel immunogenic composition, vaccine and methods for making and using the immunogenic composition and vaccine. The immunogenic composition is capable of providing an immune response and/or a protective immunity into subjects, preferably mammals, against microorganism-associated disease. The immunogenic composition includes one or more extracellular proteins isolated from a microorganism capable of providing an immune response and/or a protective immunity into subjects against microorganism-associated disease. The isolated extracellular proteins range in molecular weight from about 10,000 Da to about 220,000 Da. Suitable microorganisms may include members of the genus | 12-30-2010 |
20110020402 | Method For Identification, Isolation And Production Of Antigens To A Specific Pathogen - Described is a method for identification, isolation and production of hyperimmune serum-reactive antigens from a specific pathogen, a tumor, an allergen or a tissue or host prone to autoimmunity, said antigens being suited for use in a vaccine for a given type of animal or for humans, which is characterized by the following steps:—providing an antibody preparation from a plasma pool of said given type of animal or from a human plasma pool or individual sera with antibodies against said specific pathogren, tumor, allergen or tissue or host prone to auto-immunity,—providing at least one expression library of said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—screening said at least one expression library with said antibody preparation, identifying antigens which bind in said screening to antibodies in said antibody preparation, —screening the identified antigens with individual antibody preparations from individual sera from individuals with antibodies against said specific pathogen, tumor, allergen or tissue or host prone to auto-immunity,—identifying the hyperimmune serum-reactive antigen portion of said identified antigens and which hyperimmune serum-reactive antigens bind to a relevant portion of said individual antibody preparations from said individual sera and—optionally isolating said hyperimmune serum-reactive antigens and producing said hyperimmune serum-reactive antigens by chemical or recombinant methods. | 01-27-2011 |
20110104207 | GYRASE INHIBITORS AND USES THEREOF - The present invention relates to compounds which inhibit bacterial gyrase and pharmaceutically acceptable compositions comprising said compounds. These compounds, and compositions thereof, are useful in treating bacterial infection. Accordingly, the present invention also relates to methods for treating bacterial infections in mammals. The present invention also relates to a method for preparing these compounds. | 05-05-2011 |
20110150931 | RAPID RESPONSES TO DELAYED BOOSTER IMMUNISATIONS - Booster immunization can lead to rapid induction of protective immunity against pathogens (e.g. ≦7 days after the booster dose). This rapid response means that booster immunization can be used at short notice prior to an event that might require an activated immune response. For instance, a subject can be primed at a young age against a pathogen that typically affects more elderly subjects under specific circumstances such that, when the subject is older, the immune response can be mobilized rapidly if those specific circumstances are expected. An example would be to prime a subject against infections that are typically acquired nosocomially and then, soon before a scheduled hospital appointment, to boost their immune response so that they enter hospital in an immune-alert state. | 06-23-2011 |
20110195093 | Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers - The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. | 08-11-2011 |
20110256179 | PHARMACEUTICAL PREPARATION COMPRISING A COMBINATION OF STREPTOCOCCUS STRAINS AND LACTOBACILLUS STRAINS - A pharmaceutical preparation for prophylaxis against and treatment of | 10-20-2011 |
20110311588 | AGENTS AND TREATMENT FOR SNORING AND RESPIRATORY EFFORT RELATED AROUSALS IN SLEEP - A method for prophylaxis or treatment of respiratory effort related arousals during sleep of a subject is provided. The method comprises administering to the subject an effective amount of an agent for reducing or inhibiting infection or colonisation of the nasal cavity of the subject by | 12-22-2011 |
20120237549 | CONJUGATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR POLYSACCHARIDES - The invention provides a process for preparing a conjugate of a | 09-20-2012 |
20120244189 | TREATMENT OF INFECTIONS - The present invention is directed to improved microbial antigen vaccines, pharmaceutical compositions, immunogenic compositions and antibodies and their use in the treatment of microbial infections, particularly those of bacterial origin, including Staphylococcal origin. Ideally, the present invention is directed to a recombinant staphylococcal MSCRAMM or MSCRAMM-like proteins, or fragment thereof, with reduced binding to its host ligand, for use in therapy. | 09-27-2012 |
20120282295 | PURIFICATION OF STAPHYLOCOCCUS AUREUS TYPE 5 AND TYPE 8 CAPSULAR SACCHARIDES - The invention provides a method for releasing capsular polysaccharide from | 11-08-2012 |
20130064851 | INACTIVATED STAPHYLOCOCCAL WHOLE-CELL VACCINE - The vaccine that is protective against pathogenic bacterial species, typically staphylococcal species, and including methods to prepare said vaccine and to culture pathogenic bacteria. | 03-14-2013 |
20130280300 | Polypeptides and Immunizing Compositions Containing Gram Positive Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 10-24-2013 |
20130287813 | Polypeptides and Immunizing Compositions Containing Gram Positive Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 10-31-2013 |
20130295137 | Compositions And Methods For Treatment Of Microbial Infections - The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions. | 11-07-2013 |
20140093539 | PROTEIN A COMPOSITIONS AND METHODS OF USE - Methods and compositions for modulating an immune response in a subject are provided. Methods include administering to the subject a composition comprising an effective amount of a lymphocyte differentiation factor, e.g., protein A (PA), sufficient to modulate the immune response. Compositions include a lymphocyte differentiation factor, e.g., protein A (PA), in an amount less than 1 μg. | 04-03-2014 |
20140377309 | AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR (TLR) 13 - The present invention relates to the field of immunology. The present invention provides agonists and antagonists of Toll-like receptor (TLR) 13. In particular, the present invention provides TLR13 activating and inhibiting nucleic acids, and provides such nucleic acids for use as pharmaceutical agents. The present invention further provides in vitro methods using such nucleic acids. | 12-25-2014 |
20150343050 | Tissue Targeted Antigenic Activation of the Immune Response to Treat Cancers - The invention provides in part methods of treating cancers of a specific organ or tissue by administering a composition that is antigenically specific for one or more microbes that are pathogenic in the specific organ or tissue in which the cancer is situated. | 12-03-2015 |
20160089428 | PHARMACEUTICAL PREPARATION COMPRISING A COMBINATION OF STREPTOCOCCUS STRAINS AND LACTOBACILLUS STRAINS - A pharmaceutical preparation for prophylaxis against and treatment of | 03-31-2016 |
20160120970 | COMPOUNDS AND METHODS FOR AFFECTING CYTOKINES - The present invention discloses isolates and fractions from a phyto-percolate and methods for affecting various cytokines by administering an effective amount of one or more of said isolates or fractions to an animal. In various exemplary embodiments, the isolates are useful for the treatment of bovine, canine and swine infection or inflammation, including bovine mastitis, by regulation of TNF-a, lactoferrin, IFN-γ, IL-I β, serum amyloid-A (SAA), IL-6 and/or β-defensin associated with infection or an immune response generally. | 05-05-2016 |